Significant impacts also found to discharge rates and median
length of stay
CHICAGO–(BUSINESS WIRE)– Aerogen, the global leader in aerosol drug delivery, today announced the
results of a ground breaking study which showed a 32% reduction in the
number of patients admitted to the hospital when treated with Aerogen®
Solo vibrating mesh technology1. This breakthrough
study demonstrates the impact of a high performance aerosol drug
delivery system on patient care in the Emergency Department at St John’s
Medical Center (Detroit, Michigan) and was presented simultaneously at
both the American Association of Respiratory Care (San Antonio) and the
American College of Emergency Physicians (Las Vegas).
This Smart News Release features multimedia. View the full release here:
The findings come at a time when Emergency Departments across the
country are experiencing a sharp increase in the number of patients
presenting with respiratory disorders such as COPD, asthma and
influenza, which have more frequent exacerbations over the winter season2.
The result is pressure on hospitals to increase the number of patients
going through the Emergency Department.
“Reducing a patient’s need to be admitted means a couple of things.
First, it means that patient feels a lot better and is ready to go home,
which is great for the patient, but second, it also means one less
person who may be waiting for a bed and spending some time in the
hospital,” noted principal investigator and study co-author Robert
Dunne, MD, Vice Chair of Emergency Medicine at St. John Medical Center.
The study looked at 1,576 patients over two sequential 30-day periods in
a busy, urban emergency department. It compared the impact of
bronchodilator medication administered with Aerogen® Solo vibrating mesh
technology to treatments administered with a traditional small volume
nebulizer. The research found that Aerogen technology was statistically
associated with 32% fewer admissions to the hospital, a 75% reduction in
the amount of medication administered and a 37-minute median reduction
in the length of a patient’s stay in the Emergency Department.
“This large clinical study demonstrates the impact Aerogen
technology can have in the Emergency Department and is further
evidence of the outstanding clinical results we’ve seen when Aerogen
technology is used in critical medical units all over the world,” noted
John Power, Managing Director and CEO of Aerogen. “When patients feel
better and can go home faster, without an extended hospital stay, it
benefits everyone. This is truly great news for patients, clinicians and
hospital administrators alike.”
1.Dunne R et al. Aerosol dose matters in the Emergency Department: A
comparison of impact of bronchodilator administration with two nebulizer
systems. Poster at the American Association for Respiratory Care. 2016
2.Mackay AJ, Donaldson GC, Patel AR, Singh R, Kowlessar B and Wedzicha
JA. Detection and severity grading of COPD exacerbations using the
exacerbations of chronic pulmonary disease tool (EXACT). The European
respiratory journal : official journal of the European Society for
Clinical Respiratory Physiology. 2014;43:735-44.
is the world’s leading medical device company specializing in the
design, manufacture and commercialization of aerosol drug delivery
systems. Aerogen’s patented vibrating mesh technology turns liquid
medication into a fine particle mist, gently and effectively delivering
drugs to the lungs of critically ill patients of all ages. Aerogen’s
innovative products, such as the Aerogen® Solo and Aerogen® Ultra,
significantly improve aerosol drug delivery resulting in better patient
care throughout the Hospital.
Founded in Galway, Ireland in 1997, its North American offices are based
in Chicago, Illinois. Aerogen has grown to become the global leader in
high performance aerosol drug delivery and has partnered its technology
with the leading mechanical ventilation companies. Aerogen technology is
used by millions of patients and caregivers in over 75 countries
Marketing Manager, Americas